{
  "brand_identity": {
    "primary_colors": {
      "chinese_bronze": "#c98b27",
      "ateneo_blue": "#004567",
      "pale_cerulean": "#9bc0e2",
      "weldon_blue": "#8295ae"
    },
    "typography": {
      "family": "Roboto",
      "variants": [
        "Regular",
        "Bold"
      ],
      "source": "Google Fonts"
    },
    "design_principles": [
      "Clean stroked icons",
      "Professional imagery",
      "Consistent spacing"
    ]
  },
  "consolidated_kpis": {
    "executive_summary": {
      "total_patients_analyzed": 2470055,
      "data_sources": 3,
      "analysis_period": "2017-2025 (8+ years)",
      "key_findings": [
        "Komodo demonstrates 62% higher patient capture than IQVIA",
        "HealthVerity shows superior data quality with 100% paid claims",
        "PARAPLATIN emerges as dominant therapy across all sources",
        "80%+ patients are aged 60 and above",
        "Significant data source variations reveal market opportunities"
      ]
    },
    "data_stacking_insights": {
      "patient_pool_comparison": {
        "iqvia": {
          "total_patients": 595839,
          "diagnosis_patients": 585915,
          "procedure_patients": 532363,
          "prescription_patients": 91377,
          "market_position": "Baseline source - comprehensive claims data",
          "strength": "Strong NPI coverage for provider analysis"
        },
        "healthverity": {
          "total_patients": 908031,
          "diagnosis_patients": 904220,
          "procedure_patients": 844532,
          "prescription_patients": 140609,
          "vs_iqvia_increase": "+52%",
          "market_position": "Premium data quality with 100% paid claims",
          "strength": "Highest data completeness and reliability"
        },
        "komodo": {
          "total_patients": 966185,
          "diagnosis_patients": 961381,
          "procedure_patients": 911865,
          "prescription_patients": 109721,
          "vs_iqvia_increase": "+62%",
          "market_position": "Largest patient capture with broad coverage",
          "strength": "Maximum patient identification capability"
        }
      },
      "data_quality_matrix": {
        "claims_processing": {
          "iqvia": {
            "paid": 82,
            "rejected": 12,
            "reversed": 6
          },
          "healthverity": {
            "paid": 100,
            "rejected": 0,
            "reversed": 0
          },
          "komodo": {
            "paid": 66,
            "rejected": 17,
            "reversed": 17
          }
        },
        "npi_completeness": {
          "billing_npi": {
            "iqvia": 95,
            "healthverity": 78,
            "komodo": 92
          },
          "prescriber_npi": {
            "iqvia": 94,
            "healthverity": 76,
            "komodo": 91
          },
          "facility_npi": {
            "iqvia": 23,
            "healthverity": 28,
            "komodo": 0
          }
        },
        "demographic_coverage": {
          "gender_completeness": {
            "iqvia": 98,
            "healthverity": 99,
            "komodo": 97
          },
          "age_completeness": {
            "iqvia": 96,
            "healthverity": 98,
            "komodo": 94
          },
          "geography_coverage": {
            "iqvia": 85,
            "healthverity": 94,
            "komodo": 91
          }
        }
      }
    },
    "treatment_landscape": {
      "top_procedures": [
        {
          "product": "PARAPLATIN",
          "mechanism": "Carboplatin-based chemotherapy",
          "iqvia_patients": 306860,
          "healthverity_patients": 383886,
          "komodo_patients": 437839,
          "market_dominance": "Leading therapy across all sources",
          "clinical_significance": "Standard of care for advanced NSCLC"
        },
        {
          "product": "KEYTRUDA",
          "mechanism": "Anti-PD-1 immunotherapy",
          "iqvia_patients": 165368,
          "healthverity_patients": 213708,
          "komodo_patients": 240307,
          "market_dominance": "Major immunotherapy presence",
          "clinical_significance": "First-line and maintenance therapy"
        },
        {
          "product": "TAXOL",
          "mechanism": "Paclitaxel-based chemotherapy",
          "iqvia_patients": 142731,
          "healthverity_patients": 183693,
          "komodo_patients": 205597,
          "market_dominance": "Established chemotherapy backbone",
          "clinical_significance": "Combination therapy standard"
        }
      ],
      "prescription_leaders": [
        {
          "product": "TAGRISSO",
          "mechanism": "EGFR tyrosine kinase inhibitor",
          "iqvia_patients": 45041,
          "healthverity_patients": 42240,
          "komodo_patients": 41862,
          "target_population": "EGFR-mutated NSCLC",
          "clinical_significance": "Targeted therapy for specific biomarker"
        }
      ]
    },
    "demographic_profile": {
      "age_distribution_insights": {
        "elderly_dominance": "80%+ patients are aged 60 and above",
        "working_age_representation": "~10% in 25-59 age group",
        "pediatric_cases": "Minimal (<1%) as clinically expected",
        "clinical_implication": "Treatment decisions must consider age-related comorbidities"
      },
      "geographic_patterns": {
        "state_concentration": "Top 10 states represent 50% of patient volume",
        "urban_rural_split": "Analysis limited by facility NPI coverage",
        "regional_variations": "Treatment patterns vary by geographic region"
      }
    },
    "clinical_coding_analysis": {
      "top_diagnoses": [
        {
          "code": "C3490",
          "description": "Malignant neoplasm of unspecified part of unspecified bronchus and lung",
          "iqvia_prevalence": 81.1,
          "healthverity_prevalence": 84.2,
          "komodo_prevalence": 82.8,
          "clinical_note": "Most common primary diagnosis code"
        },
        {
          "code": "C3491",
          "description": "Malignant neoplasm of unspecified part of right bronchus and lung",
          "iqvia_prevalence": 35.5,
          "healthverity_prevalence": 42.3,
          "komodo_prevalence": 40.8,
          "clinical_note": "Laterality-specific diagnosis"
        }
      ],
      "procedure_utilization": [
        {
          "code": "J9045",
          "description": "Injection, Carboplatin, 50 mg",
          "utilization_rate": 45.5,
          "clinical_context": "Standard chemotherapy administration"
        },
        {
          "code": "J9271",
          "description": "Injection, Pembrolizumab, 1 mg",
          "utilization_rate": 26.2,
          "clinical_context": "Immunotherapy administration"
        }
      ]
    },
    "strategic_implications": {
      "data_source_strategy": [
        "Komodo offers maximum patient identification for market sizing",
        "HealthVerity provides premium quality for outcome studies",
        "IQVIA delivers comprehensive provider network analysis",
        "Multi-source approach reduces bias and increases completeness"
      ],
      "clinical_insights": [
        "PARAPLATIN dominance suggests continued importance of platinum-based therapy",
        "KEYTRUDA presence indicates immunotherapy adoption in real-world practice",
        "Age distribution aligns with NSCLC epidemiology expectations",
        "Geographic concentration suggests targeted intervention opportunities"
      ],
      "market_opportunities": [
        "62% patient identification gap between sources indicates untapped markets",
        "Data quality variations suggest partnership optimization opportunities",
        "Treatment pattern consistency validates therapeutic approaches",
        "Demographic insights enable precision targeting strategies"
      ]
    }
  },
  "eda_narrative": {
    "story_arc": {
      "chapter_1": {
        "title": "The Data Landscape Discovery",
        "narrative": "Our journey begins with three distinct lenses into the NSCLC patient universe, each revealing unique perspectives on the same clinical reality.",
        "key_metrics": [
          "2.47M total patients",
          "3 data ecosystems",
          "8+ years coverage"
        ],
        "story_hook": "What happens when we stack three major healthcare databases? The answer reshapes our understanding of NSCLC patient care."
      },
      "chapter_2": {
        "title": "The Great Patient Count Revelation",
        "narrative": "Komodo's 966K patients vs IQVIA's 596K patients tells a story of hidden patient populations and untapped market potential.",
        "key_insights": [
          "62% more patients in Komodo",
          "52% increase in HealthVerity",
          "Consistent demographic patterns"
        ],
        "clinical_significance": "These aren't just numbers - they represent real patients whose care journeys differ across data systems."
      },
      "chapter_3": {
        "title": "Treatment Patterns Emerge",
        "narrative": "PARAPLATIN's dominance across all three sources reveals the persistent importance of platinum-based chemotherapy in NSCLC care.",
        "treatment_story": "While immunotherapy gains attention, traditional chemotherapy remains the backbone of NSCLC treatment",
        "market_insights": [
          "PARAPLATIN: 440K patients (Komodo)",
          "KEYTRUDA: 240K patients",
          "Treatment consistency validates clinical guidelines"
        ]
      },
      "chapter_4": {
        "title": "Data Quality Truth",
        "narrative": "HealthVerity's 100% paid claims rate vs Komodo's 66% reveals the spectrum of data reliability in real-world evidence generation.",
        "quality_implications": "Not all healthcare data is created equal - understanding these differences is crucial for accurate insights",
        "strategic_value": "Premium data quality commands premium insights"
      },
      "chapter_5": {
        "title": "The Age Reality Check",
        "narrative": "80% of NSCLC patients are over 60, confirming epidemiological expectations while highlighting care considerations for an aging population.",
        "demographic_story": "NSCLC remains predominantly a disease of older adults, with treatment decisions requiring age-appropriate considerations",
        "future_implications": "Aging population trends will continue to shape NSCLC treatment patterns"
      },
      "conclusion": {
        "title": "Synthesis and Strategic Direction",
        "narrative": "Data stacking reveals not just what we knew, but what we didn't know we didn't know about NSCLC patient populations.",
        "key_takeaways": [
          "Multi-source analysis eliminates single-source bias",
          "Patient identification gaps represent market opportunities",
          "Data quality variations require strategic source selection",
          "Treatment patterns validate clinical guidelines",
          "Demographics confirm epidemiological expectations"
        ],
        "next_steps": "Armed with these insights, stakeholders can make informed decisions about data partnerships, market strategies, and clinical program development."
      }
    },
    "visualization_strategy": {
      "primary_charts": [
        "Line charts for trends",
        "Bar charts for comparisons",
        "Heatmaps for quality metrics"
      ],
      "color_narrative": "Chryselys bronze (#c98b27) highlights key insights, blue palette (#004567) provides professional backdrop",
      "interaction_design": "Progressive disclosure reveals deeper insights through user exploration"
    }
  },
  "dashboard_sections": [
    "Executive Overview",
    "Data Source Comparison",
    "Treatment Landscape Analysis",
    "Patient Demographics Deep-dive",
    "Data Quality Assessment",
    "Clinical Coding Patterns",
    "Strategic Implications"
  ]
}